ReviewFrontiers in immunology2026
Broad-spectrum host-targeting antivirals for rhinovirus infections: mechanisms and future perspectives.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhinovirus is the main pathogen causing common colds, acute exacerbations of asthma, chronic obstructive pulmonary disease and other respiratory diseases. Due to its numerous serotypes and the lack of common conserved viral targets, the development of traditional direct-acting antiviral drugs (DAAs) faces challenges. Host-targeting antivirals (HTAs), as an emerging strategy, provide a new approach to overcome this difficulty by interfering with the host cell factors or pathways necessary for viral replication. This review systematically presents the latest progress in host-targeted rhinovirus therapy by focusing on numerous host factors involved in rhinovirus invasion, attachment, biosynthesis, assembly and release, and immune regulation. Although the prospects are broad, the clinical transformation of this strategy still faces challenges such as safety, delivery efficiency, and individual differences. In conclusion, HTAs are expected to become a transformative treatment strategy for rhinovirus infection, especially for high-risk patient groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.